ClariVein机械化学消融治疗大隐静脉筋膜外属支的可行性与短期并发症
单中心回顾性研究纳入32例患者共33条大隐静脉功能不全肢体,行ClariVein机械化学消融,按是否存在筋膜外大隐静脉属支分为筋膜外组11条与对照组22条。全部手术技术成功,无重大并发症;筋膜外组色素沉着评分显著更高,提示处理筋膜外属支时需谨慎。
要点
- ClariVein治疗大隐静脉功能不全技术成功率高且无重大并发症
- 筋膜外大隐静脉属支存在时色素沉着评分显著升高
- 处理筋膜外属支时应警惕色素沉着风险
核心结论
- ClariVein静脉内治疗大隐静脉功能不全可安全实施,但处理筋膜外大隐静脉属支时因易致色素沉着而需谨慎。
研究设计与样本
- 单中心回顾性研究,2017年12月至2020年2月行ClariVein机械化学消融的32例患者共33条大隐静脉功能不全肢体,分为筋膜外组11条与对照组22条。
- 术后1周及1、3、6、12个月随访,记录皮肤并发症计数及四分制评分。
主要发现
- 全部33条肢体手术技术成功(100%),无重大并发症报告。
- 筋膜外组大腿远端大隐静脉深度显著低于对照组(2.64±0.5 mm vs 7.05±2.57 mm;P<.001)。
- 两组硬化剂(十四烷基硫酸钠)用量(5.45±2.02 mL vs 6.59±1.79 mL;P=.109)与消融长度(31.82±3.92 cm vs 32.95±4.05 cm;P=.449)无统计学差异。
- 筋膜外组色素沉着评分显著高于对照组(0.18±0.4 vs 0±0;P=.0401),但色素沉着计数无显著差异(2/11条[18.2%] vs 0/22条[0.0%];P=.1042)。
- 筋膜外组静脉炎与瘀斑的计数和评分略高,但差异无统计学意义。
关键数值与推荐
- 色素沉着评分:筋膜外组0.18±0.4 vs 对照组0±0;P=.0401。
- 色素沉着计数:筋膜外组2/11条(18.2%)vs 对照组0/22条(0.0%);P=.1042。
- 大隐静脉深度:筋膜外组2.64±0.5 mm vs 对照组7.05±2.57 mm;P<.001。
临床怎么用
- ClariVein可用于大隐静脉功能不全的静脉内消融,技术成功率高。
- 术前识别筋膜外大隐静脉属支,对此类病例操作时注意色素沉着风险并加强术后随访。
局限性
- 单中心回顾性设计,样本量小(33条肢体),分组非随机,随访时间最长为12个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of the present study was to investigate the occurrence of skin complications after mechanochemical ablation with the ClariVein device (Merit Medical, South Jordan, Utah) for incompetent great saphenous veins (GSVs) and compare the results in terms of the target vein characteristics, especially in the presence of an epifascial GSV tributary. METHODS: A single-center, retrospective study was performed. We reviewed 33 limbs of 32 patients with GSV insufficiency who had undergone mechanochemical ablation with the ClariVein device from December 2017 to February 2020. The 33 limbs were divided into two groups: the epifascial group, comprising 11 limbs of 11 patients, and the nonepifascial group, comprising 22 limbs of 21 patients. The patients underwent postoperative follow-up examinations at 1 week and 1, 3, 6, and 12 months. The skin complication counts and scores on a four-point scale were recorded. RESULTS: Regarding the baseline characteristics, the epifascial group showed a significantly lower GSV depth in the distal thigh region compared with the nonepifascial group (2.64 ± 0.5 mm vs 7.05 ± 2.57 mm; P < .001). No statistically significant difference was found between the two groups in terms of the sclerosant (sodium tetradecyl sulfate) volume (5.45 ± 2.02 mL vs 6.59 ± 1.79 mL; P = .109) or ablation length (31.82 ± 3.92 cm vs 32.95 ± 4.05 cm; P = .449). All ClariVein procedures were technically successful (33 of 33 limbs; 100%), and no major complications were reported. The hyperpigmentation score was significantly greater in the epifascial group than in the nonepifascial group (score, 0.18 ± 0.4 vs 0 ± 0; P = .0401), although the hyperpigmentation count was not significantly different between the two groups (2 of 11 limbs [18.2%] vs 0 of 22 limbs [0.0%]; P = .1042). Although marginally higher counts and scores were observed in terms of phlebitis and bruising in the epifascial group, these differences were not statistically significant. CONCLUSIONS: Endovenous treatment with the ClariVein device for incompetent GSVs can be performed safely. However, caution should be exercised when the epifascial GSV tributary is treated during the ClariVein procedure because of its predilection to result in hyperpigmentation.
引用
- Kwon YW, Park SW, Hwang JH, et al. Feasibility and short-term complication rate of mechanochemical ablation for epifascial tributaries of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 33186752. doi:10.1016/j.jvsv.2020.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。